Cronos Group

Report: 380 Israeli cannabis cultivators pass early licensing test

Nearly 400 medical marijuana cultivators made it through the first round of testing in Israel’s licensing process, demonstrating the high level of interest in the country’s burgeoning medical cannabis industry just three months after exports won cabinet’s approval. Just over 380 cultivators underwent police checks and land ownership verification, while another 181 applicants still are behind them […]

Read More

Cronos Group reports boosted cannabis revenue but wider losses in Q4

Cronos Group, a Toronto-based licensed cannabis party, posted sizable fourth-quarter revenue, the company said in an earnings report Tuesday, but its net loss for the period grew sharply – fueled in large part by financial reporting requirements. Cronos reported fourth-quarter revenue of 5.6 million Canadian dollars ($4.2 million) for the period ended Dec. 31, 2018, up nearly 250% […]

Read More

Canadian medical cannabis exports tripled last year, as race for European market position intensifies

Exports of medical cannabis from Canada soared last year as the country’s biggest licensed cannabis companies continued to establish beachheads in new medical markets overseas. Shipments of dried cannabis tripled to 1,460 kilograms (3,219 pounds) in 2018, compared with 500 kilograms in 2017 and only 44 kilograms in 2016. Exports of medical cannabis oil doubled […]

Read More

Amyris closes on potential $300M cannabinoid deal with biotech group Lavvan

Amyris, a California-based company focused on wellness products, said it has closed a deal potentially worth $300 million with biotech startup Lavvan to research and develop synthetic cannabinoids. The move follows that of Canada’s Cronos Group inking a $122 million deal with Boston-based Ginkgo Bioworks last September to produce lab-grown cannabinoids. Analysts at Toronto-based Paradigm Capital […]

Read More

Marijuana firm Cronos closes CA$2.4 billion investment from tobacco giant Altria

Altria Group’s record-breaking investment of 2.4 billion Canadian dollars ($1.8 billion) in Ontario-based cannabis producer Cronos Group closed Friday, completing what is so far the largest investment by a tobacco company in the cannabis space. The investment gives Altria a 45% stake in Cronos. Virginia-based Altria also has a warrant that, if exercised, would bump […]

Read More

Wall Street bank: Fears on cannabis commoditization overdone

A New York-based investment bank initiated coverage of the cannabis industry Monday, another sign that Wall Street prudence is catching up to main street excitement over the burgeoning sector. The global marijuana industry has a “base-case conservative” forecast worth roughly $50 billion in the next decade, Jefferies Group said in its initiating report, and a […]

Read More

Major Canadian pension fund loads up on cannabis stocks

One of Canada’s biggest pension managers increased its stake in Canopy Growth and took positions in three more Canadian cannabis companies recently, giving a vote of confidence to long-term investors in the booming industry. The Public Sector Pension Investment Board (PSP) – with 153 billion Canadian dollars ($130 billion) of net assets – disclosed it had purchased […]

Read More

Canadian marijuana grower Village Farms approved for Nasdaq listing

Village Farms International, a Canadian greenhouse grower with a 50% stake in British Columbia-based cannabis firm Pure Sunfarms Corp., has graduated to the Nasdaq exchange. The company says it will leave the over-the-counter markets – where it trades as VFFIF – and list on the Nasdaq Capital Market as VFF. A date for the listing […]

Read More

Victoria’s aim to be Australian ‘cannabis capital’ challenged by patient access issues

An Australian state’s ambition to be the nation’s “medical cannabis capital” is unlikely to succeed unless market access for local patients substantially improves, experts note. Patient access to medical cannabis remains a serious concern despite marked improvements over the past year. “The crux of the problem is, we can’t produce medical cannabis products for our market […]

Read More